Mei pharma reports fiscal year end 2024 cash position

San diego--(business wire)--mei pharma, inc. (nasdaq: meip) (the “company”) today reported results for its fiscal year ended june 30, 2024. previously on july 22, 2024, the company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. subsequent to that date, the company announced the engagement of oppenheimer & co., inc. to serve as the company's exclusive financial adviser to assist in the review and.
MEI Ratings Summary
MEI Quant Ranking